Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Cash from Financing Activities (2021 - 2025)

Senti Biosciences has reported Cash from Financing Activities over the past 5 years, most recently at $11.0 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $11.0 million for Q4 2025, down 78.48% from a year ago — trailing twelve months through Dec 2025 was $11.8 million (down 78.11% YoY), and the annual figure for FY2025 was $11.8 million, down 78.11%.
  • Cash from Financing Activities for Q4 2025 was $11.0 million at Senti Biosciences, up from $124000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for SNTI hit a ceiling of $232.0 million in Q2 2021 and a floor of -$485000.0 in Q3 2022.
  • Median Cash from Financing Activities over the past 5 years was $876000.0 (2022), compared with a mean of $51.8 million.
  • Biggest five-year swings in Cash from Financing Activities: crashed 100.21% in 2022 and later skyrocketed 10708.7% in 2024.
  • Senti Biosciences' Cash from Financing Activities stood at $232.0 million in 2021, then crashed by 99.62% to $876000.0 in 2022, then tumbled by 36.53% to $556000.0 in 2023, then surged by 9124.82% to $51.3 million in 2024, then plummeted by 78.48% to $11.0 million in 2025.
  • The last three reported values for Cash from Financing Activities were $11.0 million (Q4 2025), $124000.0 (Q3 2025), and $1.0 million (Q2 2025) per Business Quant data.